Valuation
- Market cap
- 9,480,000
- Revenue TTM
- $0
- Net income TTM
- $-15,800,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 20,200
- Avg volume
- 685,708
- Day's range
- $4.47 – $4.81
- Shares out
- 2,008,000
- Stochastic %K
- 0%
- Beta
- 1.56
- Analysts
- Strong Sell
- Price target
- $20.20
Company profile
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It...
Show more
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 703 980 4182
- Website
- https://quoinpharma.com
- Address
- 42127 Pleasant Forest Court, Ashburn, United States
Latest news
No headlines yet.
